BR112022021520A2 - Composição de liberação atrasada para administração peroral - Google Patents

Composição de liberação atrasada para administração peroral

Info

Publication number
BR112022021520A2
BR112022021520A2 BR112022021520A BR112022021520A BR112022021520A2 BR 112022021520 A2 BR112022021520 A2 BR 112022021520A2 BR 112022021520 A BR112022021520 A BR 112022021520A BR 112022021520 A BR112022021520 A BR 112022021520A BR 112022021520 A2 BR112022021520 A2 BR 112022021520A2
Authority
BR
Brazil
Prior art keywords
delayed release
salt
peroral administration
release composition
composition
Prior art date
Application number
BR112022021520A
Other languages
English (en)
Portuguese (pt)
Inventor
Camber Ola
Johansson Christina
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of BR112022021520A2 publication Critical patent/BR112022021520A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022021520A 2020-04-24 2021-04-23 Composição de liberação atrasada para administração peroral BR112022021520A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006074.5A GB202006074D0 (en) 2020-04-24 2020-04-24 New composition
PCT/GB2021/050993 WO2021214487A1 (en) 2020-04-24 2021-04-23 New delayed release composition for peroral administration

Publications (1)

Publication Number Publication Date
BR112022021520A2 true BR112022021520A2 (pt) 2023-01-24

Family

ID=71080159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021520A BR112022021520A2 (pt) 2020-04-24 2021-04-23 Composição de liberação atrasada para administração peroral

Country Status (26)

Country Link
US (4) US11654115B2 (cg-RX-API-DMAC10.html)
EP (2) EP4218737A1 (cg-RX-API-DMAC10.html)
JP (3) JP7418587B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230005239A (cg-RX-API-DMAC10.html)
CN (1) CN115811971A (cg-RX-API-DMAC10.html)
AU (2) AU2021258542B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022021520A2 (cg-RX-API-DMAC10.html)
CA (1) CA3180850A1 (cg-RX-API-DMAC10.html)
DK (1) DK4138789T3 (cg-RX-API-DMAC10.html)
ES (1) ES2955915T3 (cg-RX-API-DMAC10.html)
FI (1) FI4138789T3 (cg-RX-API-DMAC10.html)
GB (1) GB202006074D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20231012T1 (cg-RX-API-DMAC10.html)
HU (1) HUE062897T2 (cg-RX-API-DMAC10.html)
IL (1) IL297374B2 (cg-RX-API-DMAC10.html)
LT (1) LT4138789T (cg-RX-API-DMAC10.html)
MA (1) MA59397B1 (cg-RX-API-DMAC10.html)
MD (1) MD4138789T2 (cg-RX-API-DMAC10.html)
MX (1) MX2022013069A (cg-RX-API-DMAC10.html)
PL (1) PL4138789T3 (cg-RX-API-DMAC10.html)
PT (1) PT4138789T (cg-RX-API-DMAC10.html)
RS (1) RS64568B1 (cg-RX-API-DMAC10.html)
SI (1) SI4138789T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300289T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021214487A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202211461B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
KR20240148359A (ko) 2022-02-10 2024-10-11 바이코어 파마 아베 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
GB202201723D0 (en) * 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
JP2003325642A (ja) * 2002-05-09 2003-11-18 Sansho Pharmaceutical Co Ltd 腸溶性皮膜付き硬質空カプセルと、腸溶性皮膜付き硬質空カプセルの製造方法と、腸溶性皮膜付き硬質カプセル剤
MXPA06004029A (es) * 2003-10-10 2006-06-28 Solvay Pharm Gmbh Composicion farmaceutica que comprende un agonista del receptor de imidazolina selectivo i1 y un bloqueante del receptor de angiotensina ii.
WO2005123072A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2946774B1 (en) 2014-05-19 2020-04-22 Tillotts Pharma AG Modified release coated capsules
EP2946773A1 (en) * 2014-05-19 2015-11-25 Tillotts Pharma AG Modified release coated capsules
HK1244232A1 (zh) * 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
JPWO2017022248A1 (ja) * 2015-08-04 2018-05-24 富士カプセル株式会社 腸溶性カプセル
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
US11931341B2 (en) * 2018-03-22 2024-03-19 University Of Lowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy
JP7044360B2 (ja) * 2018-04-02 2022-03-30 三生医薬株式会社 ハードカプセル用コーティング剤及びそれを用いたハードカプセル剤の製造方法
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Also Published As

Publication number Publication date
ZA202211461B (en) 2025-02-26
EP4218737A1 (en) 2023-08-02
JP7663647B2 (ja) 2025-04-16
JP2023504292A (ja) 2023-02-02
JP7862634B2 (ja) 2026-05-19
WO2021214487A1 (en) 2021-10-28
EP4138789A1 (en) 2023-03-01
GB202006074D0 (en) 2020-06-10
EP4138789B1 (en) 2023-06-07
LT4138789T (lt) 2023-09-25
ES2955915T3 (es) 2023-12-11
US20220202729A1 (en) 2022-06-30
RS64568B1 (sr) 2023-10-31
IL297374B2 (en) 2026-05-01
HRP20231012T1 (hr) 2023-12-08
JP2025106410A (ja) 2025-07-15
KR20230005239A (ko) 2023-01-09
HUE062897T2 (hu) 2023-12-28
SMT202300289T1 (it) 2023-11-13
AU2021258542B2 (en) 2026-03-12
PT4138789T (pt) 2023-08-29
AU2026203703A1 (en) 2026-05-28
US20230364022A1 (en) 2023-11-16
MA59397B1 (fr) 2023-11-30
SI4138789T1 (sl) 2023-11-30
US12121614B2 (en) 2024-10-22
MX2022013069A (es) 2022-11-30
AU2021258542A1 (en) 2022-12-01
CA3180850A1 (en) 2021-10-28
IL297374A (en) 2022-12-01
US11654115B2 (en) 2023-05-23
US20260007608A1 (en) 2026-01-08
IL297374B1 (en) 2026-01-01
PL4138789T3 (pl) 2023-12-11
DK4138789T3 (da) 2023-09-11
FI4138789T3 (fi) 2023-08-28
JP2024001089A (ja) 2024-01-09
JP7418587B2 (ja) 2024-01-19
US20250235408A1 (en) 2025-07-24
MD4138789T2 (ro) 2023-11-30
CN115811971A (zh) 2023-03-17

Similar Documents

Publication Publication Date Title
AU2020256326B2 (en) Novel Anti-Infective Strategy Against Influenza Virus And S.aureus Coinfections
Liao et al. Germacrone inhibits early stages of influenza virus infection
EP4615506A1 (en) Use of gsk-3 activatior to modulate proteasome activity to prevent ageing associated conditions and diseases
BR112017027798A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
AbouAitah et al. Virucidal action against avian influenza H5N1 virus and immunomodulatory effects of nanoformulations consisting of mesoporous silica nanoparticles loaded with natural prodrugs
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
BR112018002304A8 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
ZA202211461B (en) New delayed release composition for peroral administration
BR112022021511A2 (pt) Composição de pó seco para administração peroral
Smee et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice
MX375427B (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion
PL217628B1 (pl) Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy
BR112022022081A2 (pt) Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonar
Kandimalla et al. Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2
EA026665B1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
EP4376864A1 (en) Therapeutic formulations from pelargonium sp. and method of use in respiratory viral infections
JP2004262924A (ja) インフルエンザウイルス感染予防剤
CN121774965A (zh) 一种靶向csde1相分离的化合物及其在抗病毒中的应用
WO2017177919A1 (zh) 一种能够抑制流感病毒pb2蛋白与rna帽结合的化合物
BR112018072669A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratamento uma doença ou condição que se beneficiaria da inibição de ido1, e, uso de um composto ou sal
CN105920004B (zh) 1,2,4-三取代哌嗪化合物在制备抗流感病毒药物中的用途
BR112018001720A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112018001716A2 (pt) composto de derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6 e composição farmacêutica contendo o mesmo
BR112020007442B1 (pt) Uso de PD-0184264 ou um sal farmaceuticamente aceitável do mesmo e composições farmacêuticas

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]